Products
Platform
Research
Market
Learn
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.38 | - |
NAV | ₹14.03 | - |
Fund Started | 16 Jan 2024 | - |
Fund Size | ₹442.67 Cr | - |
Exit Load | Exit load of 1%, if redeemed within 1 months. | - |
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹100
-
Expense Ratio
2.38
-
NAV
₹14.03
-
Fund Started
16 Jan 2024
-
Fund Size
₹442.67 Cr
-
Exit Load
Exit load of 1%, if redeemed within 1 months.
-
Returns
1 Year | 7.65% | - |
3 Year | - | - |
5 Year | - | - |
1 Year
7.65%
-
3 Year
-
-
5 Year
-
-
Holding Analysis
Equity | 98.42% | - |
Cash | -10.33% | - |
Equity
98.42%
-
Cash
-10.33%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
JB Chemicals & Pharmaceuticals Ltd. | 6.94% |
Sun Pharmaceutical Industries Ltd. | 6.81% |
Fortis Healthcare Ltd. | 6.69% |
Cipla Ltd. | 4.56% |
Laurus Labs Ltd. | 4.28% |
Krishna Institute of Medical Sciences Ltd | 4.09% |
Neuland Laboratories Ltd. | 3.20% |
Max Healthcare Institute Ltd. | 3.19% |
Sun Pharmaceutical Industries Ltd. | 3.15% |
Lupin Ltd. | 3.14% |
-
Fund Manager
Name | Trupti Agrawal | - |
Start Date | 15 May 2024 | - |
Name
Trupti Agrawal
-
Start Date
15 May 2024
-
About Fund
Description | The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. | - |
Launch Date | 16 Jan 2024 | - |
Description
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
-
Launch Date
16 Jan 2024
-